CN1288135C - 某些作为丝氨酸蛋白酶xa因子抑制剂的1－(d－环丙基甘氨酰基)－4－(哌啶－4－基)哌嗪化合物 - Google Patents

某些作为丝氨酸蛋白酶xa因子抑制剂的1－(d－环丙基甘氨酰基)－4－(哌啶－4－基)哌嗪化合物 Download PDF

Info

Publication number
CN1288135C
CN1288135C CNB038074141A CN03807414A CN1288135C CN 1288135 C CN1288135 C CN 1288135C CN B038074141 A CNB038074141 A CN B038074141A CN 03807414 A CN03807414 A CN 03807414A CN 1288135 C CN1288135 C CN 1288135C
Authority
CN
China
Prior art keywords
compound
formula
piperazine
salt
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038074141A
Other languages
English (en)
Chinese (zh)
Other versions
CN1642914A (zh
Inventor
M·R·维利
G·L·恩格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1642914A publication Critical patent/CN1642914A/zh
Application granted granted Critical
Publication of CN1288135C publication Critical patent/CN1288135C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB038074141A 2002-04-01 2003-03-24 某些作为丝氨酸蛋白酶xa因子抑制剂的1－(d－环丙基甘氨酰基)－4－(哌啶－4－基)哌嗪化合物 Expired - Fee Related CN1288135C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36852302P 2002-04-01 2002-04-01
US60/368,523 2002-04-01

Publications (2)

Publication Number Publication Date
CN1642914A CN1642914A (zh) 2005-07-20
CN1288135C true CN1288135C (zh) 2006-12-06

Family

ID=28791889

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038074141A Expired - Fee Related CN1288135C (zh) 2002-04-01 2003-03-24 某些作为丝氨酸蛋白酶xa因子抑制剂的1－(d－环丙基甘氨酰基)－4－(哌啶－4－基)哌嗪化合物

Country Status (24)

Country Link
US (1) US7166606B2 (enExample)
EP (1) EP1492767B1 (enExample)
JP (1) JP2005531529A (enExample)
KR (1) KR20040094892A (enExample)
CN (1) CN1288135C (enExample)
AT (1) ATE303990T1 (enExample)
AU (1) AU2003218147A1 (enExample)
BR (1) BR0308870A (enExample)
CA (1) CA2478340A1 (enExample)
CR (1) CR7497A (enExample)
DE (1) DE60301569T2 (enExample)
DK (1) DK1492767T3 (enExample)
EA (1) EA007300B1 (enExample)
EC (1) ECSP045329A (enExample)
ES (1) ES2248737T3 (enExample)
HR (1) HRP20040900B1 (enExample)
IL (1) IL164018A0 (enExample)
MX (1) MXPA04009640A (enExample)
NO (1) NO20044688L (enExample)
NZ (1) NZ535402A (enExample)
PL (1) PL373066A1 (enExample)
UA (1) UA76849C2 (enExample)
WO (1) WO2003084929A1 (enExample)
ZA (1) ZA200407418B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6834308B1 (en) 2000-02-17 2004-12-21 Audible Magic Corporation Method and apparatus for identifying media content presented on a media playing device
US7363278B2 (en) 2001-04-05 2008-04-22 Audible Magic Corporation Copyright detection and protection system and method
US8972481B2 (en) 2001-07-20 2015-03-03 Audible Magic, Inc. Playlist generation method and apparatus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2018093716A1 (en) * 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
WO1999011657A1 (en) 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. 1-amino-7-isoquinoline derivatives as serine protease inhibitors
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
DE60224805T2 (de) * 2001-07-26 2009-01-22 Eli Lilly And Co., Indianapolis 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine und -piperidine als faktor-xa-antagonisten

Also Published As

Publication number Publication date
US20050096328A1 (en) 2005-05-05
NO20044688L (no) 2004-10-29
BR0308870A (pt) 2005-01-04
WO2003084929A1 (en) 2003-10-16
ZA200407418B (en) 2005-09-15
US7166606B2 (en) 2007-01-23
MXPA04009640A (es) 2005-01-11
EA200401290A1 (ru) 2005-02-24
PL373066A1 (en) 2005-08-08
CR7497A (es) 2005-01-17
ES2248737T3 (es) 2006-03-16
HK1070363A1 (en) 2005-06-17
WO2003084929A8 (en) 2004-05-21
CN1642914A (zh) 2005-07-20
DK1492767T3 (da) 2005-11-28
EP1492767A1 (en) 2005-01-05
IL164018A0 (en) 2005-12-18
HRP20040900B1 (en) 2006-02-28
HRP20040900A2 (en) 2004-12-31
KR20040094892A (ko) 2004-11-10
DE60301569D1 (de) 2005-10-13
UA76849C2 (uk) 2006-09-15
EA007300B1 (ru) 2006-08-25
ATE303990T1 (de) 2005-09-15
ECSP045329A (es) 2004-11-26
NZ535402A (en) 2006-02-24
EP1492767B1 (en) 2005-09-07
AU2003218147A1 (en) 2003-10-20
DE60301569T2 (de) 2006-06-14
JP2005531529A (ja) 2005-10-20
CA2478340A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
CN1066445C (zh) 芳酰基哌啶衍生物
CN1274288A (zh) 含肽的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
CN1376063A (zh) 环胺ccr3拮抗剂
CN1274283A (zh) 含喹啉的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
CN1072667C (zh) 含咪唑取代基的巯基烷基肽基化合物及其用作基质金属蛋白酶(mmp)和/或肿瘤坏死因子(tnf)抑制剂
CN1134695A (zh) 具有血小板凝聚抑制作用的新颖化合物
CN1288135C (zh) 某些作为丝氨酸蛋白酶xa因子抑制剂的1－(d－环丙基甘氨酰基)－4－(哌啶－4－基)哌嗪化合物
CN1212835C (zh) 含异羟肟酸酯的半胱氨酸和丝氨酸蛋白酶抑制剂
CN1414956A (zh) 作为mip抑制剂的经取代的哌嗪衍生物
CN1341095A (zh) 用于强化胆碱能活性的酰胺化合物
US7427632B2 (en) Factor Xa inhibitors
HK1050005A1 (zh) 氮杂环烷酮丝氨酸蛋白酶抑制剂
US7265121B2 (en) Chemical compounds
CN1352641A (zh) 用于治疗整联蛋白介导的疾病的异哌啶甲酰胺
CN1350525A (zh) 1,3,4－噁二唑衍生物及其制备方法
HK1070363B (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa
US7297706B2 (en) Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders
CN1174982C (zh) 抑制凝血酶的二酮哌嗪衍生物
HK1029791A (en) O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
HK1000889A (en) (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazin-1-yl]phenoxy}butyric acid as cellular adhesion inhibitor
HK1100442A (en) Butyrylcholinesterase selective inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061206